Oxytocin is under clinical development by OptiNose and currently in Phase II for Autism Spectrum Disorder (ASD). According to GlobalData, Phase II drugs for Autism Spectrum Disorder (ASD) have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Oxytocin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oxytocin (OPN-300) is under development for the treatment of autism and Prader-Willi Syndrome. The drug candidate is delivered through nasal route. The drug candidate is developed based on OptiNose bi-directional breath powered delivery technology. This technology utilizes the normal breath of the patient in order to administer the drug beyond the nasal valve into the targeted areas of the nasal cavity.
OptiNose is a specialty pharmaceutical company. It offers various products such as fluticasone propionate and sumatriptan nasal powder. Its products are used in the therapeutic areas of nasal inflammatory diseases, nasal congestion and obstruction, chronic rhinosinusitis, facial pain and pressure, drainage and postnasal drip, nasal polyps, autism, narcolepsy and Parkinson’s diseases. OptiNose developed powder delivery device with a disposable drug-containing section and liquid delivery device for medication-carrying airflow into nasal cavity. The company utilizes exhalation delivery system technology for treating neurological or psychiatric disorders, and central nervous system disorders. It has operations in the US, Norway and the UK. OptiNose is headquartered in Yardley, Pennsylvania, the US.
For a complete picture of Oxytocin’s drug-specific PTSR and LoA scores, buy the report here.